Abstract
Complex, interrelated systems exist to maintain the fluidity of the blood in the vascular system while allowing for the rapid formation of a solid blood clot to prevent hemorrhaging subsequent to blood vessel injury. These interrelated systems are collectively referred to as haemostasis. The components involved in the haemostatic mechanism consist of vessel walls, platelets, coagulation factors, inhibitors, and the fibrinolytic system. In the broadest sense, a series of cascades involving coagulation proteins and enzymes, as well as cell surfaces (platelets and endothelial cells), work together to generate thrombin, the key enzyme in coagulation, subsequently leading to the formation of a fibrin clot. However, there also exist direct and indirect inhibitors of thrombin to ensure that clot formation does not go uncontrolled. Once the fibrin clot is formed, the fibrinolytic system ensures that the clot is lysed so that it does not become a pathological complication. Taken together, the systems exist to balance each other and maintain order. The balance of coagulation and fibrinolysis keeps the haemostatic system functioning efficiently.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Andrew M, Paes B, Johnston M (1990) Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 12:95–104
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P (1987) Development of the human coagulation system in the full-term infant. Blood 70:165–172
Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P (1988) Development of the human coagulation system in the healthy premature infant. Blood 72:1651–1657
Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L (1992) Maturation of the hemostatic system during childhood. Blood 80:1998–2005
Johnston M, Zipursky A (1980) Microtechnology for the study of the blood coagulation system in newborn infants. Can J Med Technol 42: 159–164
Andrew M (1995) Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 74: 415–425
Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD (2004) Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:645S–687S
Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, Mernstein M, Brisson L, Cairney B, DeSai D, Grant R, Isreals S, Jardine L, Luke B, Massicotte P, Silva M (1994) Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83:1251–1257
Andrew M (1997) The relevance of developmental hemostasis to hemorrhagic disorders of newborns. Semin Perinatol 21:70–85
Sutor A (1992) Thrombosis in the newborn and infants. In: Poller L, Thomson J (eds) Thrombosis and its management. Churchill Livingstone, Edinburgh, pp 126–133
Kurachi K, Davie EW (1977) Activation of human factor XI (plasma thromboplastin antecedent) by factor XIIa (activated Hageman factor). Biochemistry 16:5831–5839
Nemerson Y (1966) The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 5:601–608
Hoffman M, Monroe DM, Oliver JA, Roberts HR (1995) Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 86:1794–1801
Nemerson Y (2007) Tissue factor and hemostasis. Blood 71:1–8
Naito K, Fujikawa K (1991) Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 266:7353–7358
Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J (1987) The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 243:579–588
Ofosu FA, Liu L, Freedman J (1996) Control mechanisms in thrombin generation. Semin Thromb Hemost 22:303–308
Cade JF, Hirsh J, Martin M (1969) Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn. Br Med J 2:281–283
Gitlin D, Biasucci A (1969) Development of gamma G, gamma A, gamma M, beta IC-beta IA, C 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha 1-antitrypsin, orosomucoid, beta-lipoprotein, alpha 2-macroglobulin, and prealbumin in the human conceptus. J Clin Invest 48:1433–1446
Zilliacus H, Ottelin AM, Mattsson T (1966) Blood clotting and fibrinolysis in human foetuses. Biol Neonat 10:108–112
Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y (1996) Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 88:900–906
Andrew M, Karpatkin M (1982) A simple screening test for evaluating prolonged partial thromboplastin times in newborn infants. J Pediatr 101:610–612
Gordon EM, Ratnoff OD, Saito H, Gross S, Jones PK (1980) Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn. Am J Pediatr Hematol Oncol 2:213–216
Mazurier C, Daffos F, Forestier F (1992) Electrophoretic and functional characteristics of the von Willebrand factor in human fetal plasma. Br J Haematol 81:263–270
Witt I, Müller H, Künzer W (1969) Evidence for the existence of foetal fibrinogen. Thromb Diath Haemorrh 22:101–109
Francis JL, Armstrong DJ (1982) Sialic acid and enzymatic desialation of cord blood fibrinogen. Haemostasis 11:223–228
Lerant I, Kovacs T, Papp B, Mandl J, Lambin P, Machovich R (1990) Interaction of thrombin with endothelial cells in the presence of fibrinogen and alpha 2-macroglobulin. Haematologia (Budap) 23:161–169
Sie P, Ofosu F, Fernandez F, Buchanan MR, Petitou M, Boneu B (1986) Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 64:707–714
Tollefsen DM, Pestka CA, Monafo WJ (1983) Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258:6713–6716
Mascellani G, Liverani L, Bianchini P, Parma B, Torri G, Bisio A, Guerrini M, Casu B (1993) Structure and contribution to the heparin cofactor II-mediated inhibition of thrombin of naturally oversulphated sequences of dermatan sulphate. Biochem J 296:639–648
Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP (1993) Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 91:1877–1883
Prager NA, Abendschein DR, McKenzie CR, Eisenberg PR (1995) Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots. Circulation 92:962–967
Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 86:385–391
Hogg PJ, Jackson CM (1989) Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci U S A 86:3619–3623
Bendayan P, Boccalon H, Dupouy D, Boneu B (1994) Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb Haemost 71:576–580
Monagle PT, Andrew M (2000) Hemorrhagic and thromboembolic complications during infancy and childhood. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis: basic principles and clinical practice. Lippincott Williams & Wilkins, Philadelphia, PA, pp 1053–1070
Schmidt B, Mitchell L, Ofosu FA, Andrew M (1989) Alpha-2-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma. Thromb Haemost 62:1074–1077
Levine JJ, Udall JN Jr, Evernden BA, Epstein MF, Bloch KJ (1987) Elevated levels of alpha 2-macroglobulin-protease complexes in infants. Biol Neonate 51:149–155
Mitchell L, Piovella F, Ofosu F, Andrew M (1991) Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 78:2299–2304
Dahlback B (1995) The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 77:1–43
Schwarz HP, Mutean W, Watzke H, Richter B, Griffin JH (1988) Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood 71:562–565
Menashi S, Aurousseau MH, Gozin D, Daffos F, D’Angelo A, Forestier F, Boffa MC (1999) High levels of circulating thrombomodulin in human foetuses and children. Thromb Haemost 81:906–909
Knöfler R, Hofmann S, Weissbach G, Kuhlisch E, Neef B, Otte M, Pargac N, Nachtrodt G (1998) Molecular markers of the endothelium, the coagulation and the fibrinolytic systems in healthy newborns. Semin Thromb Hemost 24:453–461
Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr (1989) Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518–520
Broze GJ Jr (1995) Tissue factor pathway inhibitor. Thromb Haemost 74:90–93
Lindahl AK (1997) Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 33:286–291
Sandset PM (1996) Tissue factor pathway inhibitor (TFPI)—an update. Haemostasis 26: 156–165
Camici M, Sagripanti A (1999) Tissue factor pathway inhibitor. Minerva Med 90:25–32
Lindahl AK, Jacobsen PB, Sandset PM, Abildgaard U (1991) Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis 2:713–721
Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K (1994) Tissue factor pathway inhibitor in infants and children. Thromb Res 73:441–446
Shah JK, Mitchell LG, Paes B, Ofosu FA, Schmidt B, Andrew M (1992) Thrombin inhibition is impaired in plasma of sick neonates. Pediatr Res 31:391–395
Andrew M, Schmidt B, Mitchell L, Paes B, Ofosu F (1990) Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 63:27–30
Fischer AM, Tapon-Bretaudiere J, Bros A, Josso F (1981) Respective roles of antithrombin III and alpha 2 macroglobulin in thrombin inactivation. Thromb Haemost 45:51–54
Andrew M, Mitchell L, Berry L, Paes B, Delorme M, Ofosu F, Burrows R, Khambalia B (1992) An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus. J Clin Invest 89:321–326
Suarez CR, Menendez CE, Walenga JM, Fareed J (1984) Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic status. Semin Thromb Hemost 10:280–284
Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD (1987) Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 80:1527–1534
Andrew M, Mitchell L, Vegh P, Ofosu F (1994) Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 72:836–842
Collen D, Lijnen HR (1991) Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114–3124
Francis CW, Marder VJ (1992) Physiologic regulation and pathologic disorders of fibrinolysis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: basic principles and clinical practice. JB Lippincott, Philadelphia, PA, pp 1076–1103
Barrett AJ (1981) Alpha 2-macroglobulin. Methods Enzymol 80:737–754
Bajzar L (2000) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20:2511–2518
Corrigan JJ Jr, Sleeth JJ, Jeter M, Lox CD (1989) Newborn’s fibrinolytic mechanism: components and plasmin generation. Am J Hematol 32:273–278
Ginsberg JS, Hirsh J, Rainbow AJ, Coates G (1989) Risks to the fetus of radiologic procedures used in the diagnosis of maternal venous thromboembolic disease. Thromb Haemost 61:189–196
Nesheim M (2003) Thrombin and fibrinolysis. Chest 124:33S–39S
Andrew M, Brooker L, Leaker M, Paes B, Weitz J (1992) Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration. Thromb Haemost 68:325–330
Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 188S–203S
Declerck PJ, Moreau H, Jespersen J, Gram J, Kluft C (1993) Multicenter evaluation of commercially available methods for the immunological determination of plasminogen activator inhibitor-1 (PAI-1). Thromb Haemost 70: 858–863
Gram J, Declerck PJ, Sidelmann J, Jespersen J, Kluft C (1993) Multicentre evaluation of commercial kit methods: plasminogen activator inhibitor activity. Thromb Haemost 70: 852–857
Stevenson KJ, Easton AC, Curry A, Thomson JM, Poller L (1986) The reliability of activated partial thromboplastin time methods and the relationship to lipid composition and ultrastructure. Thromb Haemost 55: 250–258
D’Angelo A, Seveso MP, D’Angelo SV, Gilardoni F, Dettori AG, Bonini P (1990) Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 94:297–306
Acknowledgments
Anthony Chan is supported by the Bayer Thrombosis and Haemostasis Research Grant.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Humana Press
About this protocol
Cite this protocol
Chan, A.K.C., Paredes, N. (2013). The Coagulation System in Humans. In: Monagle, P. (eds) Haemostasis. Methods in Molecular Biology, vol 992. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-339-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-339-8_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-338-1
Online ISBN: 978-1-62703-339-8
eBook Packages: Springer Protocols